Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-08-23
2005-08-23
Cook, Rebecca (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
Reexamination Certificate
active
06933287
ABSTRACT:
A method of treating tumors with radiation is disclosed, wherein the tumor is sensitized by administering a tumor sensitizing agent comprising 5-chloro-2′-deoxycytidine, 4-N-methyl FdC and a cytidine deaminase inhibitor to a patient having the tumor. The tumor is then subjected to radiation.
REFERENCES:
patent: 4894364 (1990-01-01), Greer
patent: 5985266 (1999-11-01), Link, Jr. et al.
patent: WO 85/01871 (1985-05-01), None
patent: WO 96/26743 (1996-09-01), None
Greer et al., Int. J. Ratiat. Oncol., Biol., Phys. (1992), 22(3), 505-10 Abstract Only.
Santos, O, Perez, L, Briggle, T, Boothman, D, Greer, S. 1990. Radiation, pool size and incorporation studies in mice with 5-chloro-2′-deoxycytidine.Int. J. Radiat. Oncol. Biol. Phys.19:357-365.
Greer, S, Santos, O, Gottlieb, C, Schwade, J., Marion, S. 1990. 5-Chlorodeoxycytidine, a radiosensitizer effective against RIF-1 and Lewis lung carcinoma, is also effective against a DMBA-induced mammary adenocarcinoma and the EMT-6 tumor in BALB/c mice.Int. J. Rad. Oncol. Biol. Phys.22:505-510.
Greer, S, Schwade, J, Marion, S. 1995. Five-chlorodeoxycytidine and biomodulators of its metabolism result in fifty to eighty percent cures of advanced EMT-6 tumors when used with fractionated radiation.Int. J. Rad. Oncol. Biol. Phys.32:1059-1069.
Kim, C-H., Marquez, V., Mao, D., Haines, D., McCormack, J. 1986. Synthesis of pyrimidin-2-one nucleoside as acid-stable inhibitors of cytidine deaminase.J. Med. Chem 29:1374-1380.
Marquez, V. 1994. Inhibition of cytidine deaminase: mechanism and effects of the metabolism of antitumor agents. In:Developments in Cancer Chemotherapy,Robert I. Glazer, ed, CRC Press, Boca Raton, FL, pp. 92-114.
Kelly, J., Driscoll, J., McCormack, J., Roth, J., Marquez, V. 1986. Furanose-pyranose: isomerization of reduced pyrimidine and cyclic urea ribosides.J. Med. Chem. 29:2351-2358.
Wempen, I., Duschinsky, R., Kaplan, L., and Fox, J. 1961. Organic and biological chemistry. Thiation of Nucleosides. IV. The synthesis of 5-fluoro-2′-deoxycytidine and related compounds.J. Amer. Chem. Soc. 83:4755-4766.
Russell, K., Rice, G., Brown, J. 1986. In vivo and in vitro radiation sensitization by the halogenated pyrimidine 5-chloro-2′-deoxycytidine.Cancer Res. 46:2883-2887.
Kinsella, T., Kunugi, K., Vielhuber, K., McCulloch, W., Liu, S-H., and Cheng, Y-C. 1994. An in vivo comparison of oral 5-Iodo-2′-deoxyuridine and 5-iodo-2-pyrimidinone-2′doexyribose toxicity, pharmacokinetics, and DNA incorporation in athymic mouse tissues and the human colon cancer xenograft, HCT-116. Cancer Res. 54:2695-2700.
Wataya, Y., Santi, D., Hansch, C. 1977. Inhibition ofLactobacillus caseithymidylate synthetase by 5-substituted 2′-deoxyuridylates. Preliminary quantitative structure-activity relationship.J. Med. Chem.20: 1469-1473. In: Balzarini, J., DeClerq, E., Mertes, M., Shugar, D., Torrence, P. 1982. 5-Substituted 2′-deoxyuridines: Correlation between inhibition of tumor cell growth and inhibition of thymidine kinase and thymidylate synthetase.Biochem. Pharmacol. 31:3673-3682.
Wataya, Y., Santi, D. 1975. Thymidylate synthetase catalyzed dehalogenation of 5-bromo- and 5-iodo-2′-deoxyuridylate.Biochem. Biophys. Res. Commun.67:818-823.
Caradonna, S, Cheng, Y-C. 1980. The role of deoxyuridine triphosphate nucleotidohydrolase, uracil-DNA glycosylase, and DNA polymerase α in the metabolism of FUdr in human tumor cells.Mol. Pharmacol.18:513-520.
Hirota, Y, Yoshioka, A, Tanaka, S, et al. 1989. DNA double-strand breaks, and cell death caused by 2-chlorodeoxyadenosine in mouse FM3A cells.Cancer Res.49:915-919.
Jones, P, Taylor, S. 1980. Cellular differentiation, cytidine analogs, and DNA methylation.Cell.20:85-93.
Kaysen, J, Spriggs, D, Kufe, D. 1986. Incorporation of 5-fluorodeoxycytidine and metabolites into nucleic acids of human MCF-7 breast carcinoma cells.Cancer Res.46:4534-4538.
Osterman, D., DePillis, G., Wu, J. Matsuda, A., Santi, D.1988. 5-Fluorocytosine in DNA is a mechanism-based inhibitor of HhaI methylase.Biochemistry.27:5204-5210.
Yang, A,. Shen, J-C, Zingg, J-M, Jones P. 1995. HhaI and HpaII DNA methyltransferase bind DNA mismatches, methylate uracil and block DNA repair.Nucl. Acids Res.23:1380-1387.
Jones, P, Rideout, W.,III, Shen, J-C, et al. 1992. Methylation, mutation and cancer.BioEssays.4:33-36.
El-Deiry, W., Nelkin, B., Celano, P., Yen, C., Falco, J., Hamilton, S., Baylin, S. 1991. High expression of the DNA methyltransferase gene characterizes human neoplastic cells and progression stages of colon cancer.Proc. Natl. Acad. Sci. USA.88:3470-3474.
Baylin, S. and Herman, J. 2000. Promoter hypermethylation and gene silencing in cancer.Advances in Gene Tech: DNA, RNA and Cancer.Miami Nature Biotechnology Winter Symposium, p. 43.
Wollner et al. Abstract, “Toxicity of Hepatic Arterial 5 Bromo-2′-Deoxyuridine Followed by Yttrium-90 Microspheres in Dogs”, Proc. Am. Soc. Clin. Oncol. Annu. Meet., May 4-6, 1986, vol. 5, p. 46.
Boothman et al. Abstract, “Potentiation of Halogenated Pyrimidine Radiosensitizers in Human Carcinom Cells by Beta.-1apachone(3,4-dihydro-2,2-dimethyl-2H-naphtho'1,2-b!pyra 5,6-dione), a Novel DNA Repair Inhibitor”, Cancer Res. (1987), vol. 47, pp. 5361-5366.
Perez et al. Abstract, “Marked Radiosensitization of Cells in Culture to X-Ray by 5-chlorodeoxycytidine Coadministered with Tetrahydrouridine, and Inhibitors of Pyrimidine Biosynthesis”, Int. J. Radiat. Oncol., Biol., Phys., (1984), vol. 10, pp. 1453-1458.
Zucchetti et al. Abstract, “Temozolomide-Induced Differentiation of K562 Leukemia Cells is not Mediated by Gene Hypomethylation”, Biochem. Pharmacol. (1989), vol. 38, pp. 2069-2075.
Mundinger et al. Abstract, “Post-Operative Stereotactic Curie-Therapy Using the Iridium-192 GammaMed Contact Irradiation Apparatus Combined with Radio-Sensitizers in Treating Multiform Glioblastomas”, ACTA Neurochirurgica, vol. 42, pp. 73-77 (1978).
Greer et al. Abstract, “5-Chlorodeoxycytidinie, a Radiosensitizer Effective Against RIF-1, and Lewi Lung Carcinoma, is Also Effective Against a DMBA-Induced Mammary Adenocarcinoma and the EMT-6 Tumor in BALB/c Mice”, Int. J. Radiat. Oncol., Biol., Phys. (1992), vol. 22, pp. 505-510.
Kalinich et al. Abstract, “Radioprotective Properties of DNA Methylation-Disrupting Agents”, International Journal of Radiation Biology, (1991), vol. 59, pp. 1217-1226.
Thibault et al. Abstract, “A Phase II Study of 5-aza-2′deoxycytidine (decitabine) in Hormone Independent Metastatic (D2) Prostate Cancer”, http://www.Oncolink.Com Cancernet/98/Aug/708471.HTML&50, Tumori, vol. 84, pp. 87-89 (1998).
Lawrence et al. Abstract, “Selective Radiosensitization and Cytotoxicity of Human Melanoma Cells using Halogentated Deoxycytidines and Tetrahydrouridine Retrieved from STN”, Int. J. Radiat. Oncol. Biol. Phys. (1989). pp. 1243-1246.
Cook Rebecca
Rothwell Figg Ernst & Manbeck P.C.
LandOfFree
Dramatic simplification of a method to treat neoplastic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dramatic simplification of a method to treat neoplastic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dramatic simplification of a method to treat neoplastic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3476716